<DOC>
	<DOCNO>NCT01740375</DOCNO>
	<brief_summary>To investigate role esophagectomy complete responder preoperative chemoradiotherapy squamous cell carcinoma esophagus , patient randomize either observation esophagectomy concurrent chemoradiotherapy .</brief_summary>
	<brief_title>Role Esophagectomy Complete Responders CCRT</brief_title>
	<detailed_description>After completion concurrent chemoradiotherapy , patient reassed visited multidisplinary clinic , , randomize either observation esophagectomy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Histologically proven squamous cell carcinoma intrathoracic esophagus 2 . Surgically resectable ( cT3 , cT4a and/or disease lymph node metastasis AJCC 7th ed ) esophageal cancer , determine Endoscopic Ultra Sound ( EUS ) , chest CT PETCT 3 . No prior treatment esophageal cancer 4 . Age : 2070 year 5 . ECOG performance status 0 , 1 2 6 . Adequate hematological , renal , hepatic , pulmonary cardiac function define 6.1 Granulocytes &gt; 1,500/microliter , Platelets &gt; 75,000/microliter 6.2 Creatinine &lt; 1.5 mg/dL ( CCr &gt; 50 mg/mL ) , 6.3 Total bilirubin &lt; 1.5 mg/dL 6.4 ALT AST &lt; 2.5 Ã— upper normal limit 6.5 FEV1 &gt; =1.5 L/min 6.6 Ejection fraction &gt; = 45 % 7 . Nonpregnant , nonlactating female patient . Sexually active patient childbearing potential must implement effective contraceptive practice study treat chemotherapy 8 . Written , voluntary inform consent 1 . Subtypes squamous cell carcinoma 2. cT1N0M0 , cT2N0M0 esophageal cancer situ carcinoma 3 . Invasion recurrent laryngeal , phrenic sympathetic nerve 4 . Invasion tracheobronchial tree presence tracheoesophageal fistula 5 . Invasion major vessel ( vena cava , azygos vein aorta ) tumor 6 . Malignant pleural effusion ( document cytospin cytology ) 7 . Cervical esophageal cancer 8 . Paraaortic lymph node metastasis 9 . Past current history malignancy entry diagnosis except nonmelanomatous skin cancer , curatively treat carcinoma situ cervix , curatively treat early gastric cancer endoscopic mucosal resection cure malignancy 5 year prior enrollment 10 . Previous chemotherapy prior history radiotherapy interfering plan radiotherapy per protocol 11 . Patients known history HIV seropositivity HCV ( + ) . Patients HBV ( + ) eligible . However , primary prophylaxis use antiviral agent ( i.e . lamivudine , etc ) recommend HBV carrier prevent HBV reactivation whole treatment period . 12 . Other serious illness medical condition A. Unstable cardiac disease ( i.e . congestive heart failure , arrhythmia , symptomatic coronary artery disease ) despite treatment , myocardial infarction within 6 month prior study entry B . History significant neurologic psychiatric disorder include dementia seizure C. Active uncontrolled infection ( viral , bacterial fungal infection ) D. Other serious medical illness 13 . New York heart Association Class III/IV history active angina . Documented myocardial infarction within 6 month precede registration . Patients history significant ventricular arrhythmia require medication congestive heart failure . History 2nd 3rd degree heart block . 14 . Active infection serious underlie medical condition would impair ability patient receive plan treatment 15 . Dementia alter mental status would prohibit understanding give informed consent 16 . Uncontrolled diabetes mellitus : fast glucose &gt; 150 mg/dL patient require insulin therapy glycemic control ; fast glucose &gt; 150 mg/dL patient require insulin therapy glycemic control ;</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>